EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Finerenone in Persons with Chronic Kidney Disease without Diabetes

Hiddo J L Heerspink iD, Brendon L Neuen, Rajiv Agarwal iD, David Z I Cherney, Carolyn S P Lam, Katherine R Tuttle iD, Christoph Wanner, Pantelis Sarafidis, Niels Jongs, J David Smeijer, Meike Brinker, Nicole Rethemeier iD und 7 weitere

New England Journal of Medicine · 06.08.2026 · 395 (6) · 533-545

DOI: 10.1056/nejmoa2604625 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 06.08.2026. Verfasst von Hiddo J L Heerspink und 18 weiteren Autor:innen. Beteiligte Einrichtung: George Institute for Global Health, University of New South Wales, Sydney. Hauptthemen laut MEDLINE: Albuminuria, Cardiovascular Diseases, Naphthyridines, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Bayer AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbuminuriaCardiovascular DiseasesNaphthyridinesRenal Insufficiency, ChronicHeart FailureAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodGlomerular Filtration RateMineralocorticoid Receptor AntagonistsHyperkalemiaHospitalizationKidney Failure, ChronicAdultTreatment Outcome

Substanzen

finerenoneMineralocorticoid Receptor AntagonistsNaphthyridines

Autor:innen und Institutionen

  • George Institute for Global Health, University of New South Wales, Sydney.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Department of Renal Medicine, Royal North Shore Hospital, Sydney.
  • Division of Nephrology, Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis.
  • Division of Nephrology, University Health Network, Toronto General Hospital, University of Toronto, Toronto.
  • National Heart Centre Singapore, Singapore.

ORCID-Profile: Hiddo J L Heerspink, Rajiv Agarwal, Katherine R Tuttle, Nicole Rethemeier

Förderung

  • Bayer AG

Zitieren

APA

Heerspink, H. J. L., Neuen, B. L., Agarwal, R., Cherney, D. Z. I., Lam, C. S. P., Tuttle, K. R., Wanner, C., Sarafidis, P., Jongs, N., Smeijer, J. D., Brinker, M., Rethemeier, N., Schloemer, P., Vesterinen, P., Goldsbury, D., Dizayee, S., Mares, J. W., Perkovic, V., & FIND-CKD Investigators (2026). Finerenone in Persons with Chronic Kidney Disease without Diabetes. New England Journal of Medicine, 395(6), 533-545. https://doi.org/10.1056/nejmoa2604625

Vancouver

Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, et al. Finerenone in Persons with Chronic Kidney Disease without Diabetes. New England Journal of Medicine. 2026;395(6):533-545. doi:10.1056/nejmoa2604625

BibTeX
@article{Heerspink2026,
  author = {Heerspink, Hiddo J L and Neuen, Brendon L and Agarwal, Rajiv and Cherney, David Z I and Lam, Carolyn S P and Tuttle, Katherine R and Wanner, Christoph and Sarafidis, Pantelis and Jongs, Niels and Smeijer, J David and Brinker, Meike and Rethemeier, Nicole and Schloemer, Patrick and Vesterinen, Paula and Goldsbury, David and Dizayee, Sara and Mares, Jon W and Perkovic, Vlado and FIND-CKD Investigators, FIND-CKD Investigators},
  title = {Finerenone in Persons with Chronic Kidney Disease without Diabetes},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {6},
  pages = {533--545},
  doi = {10.1056/nejmoa2604625}
}
Kostenlos starten →